Nachrichten zur Fate Therapeutics, Inc. Aktie

Los Angeles, California--(Newsfile Corp. - January 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces…

Fate Therapeutics's (NASDAQ:FATE) short percent of float has fallen 4.62% since its last report. The company recently reported that it…

Boston, Massachusetts--(Newsfile Corp. - January 6, 2023) - Block & Leviton is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) for potential…

Shares of Fate Therapeutics Inc. FATE plunged 56.8% in premarket trading, putting them on track for a record one-day selloff,…

Stocks to Watch: World Wrestling Ent., Spruce Bios, CytomX Therapeutics, Graphite Bio, Fate Therapeutics...…

Fate Therapeutics Shares Plunge 52% On Terminated Collaboration with Janssen, Layoff Plans...…

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and…

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest…

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity…

Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and…

FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into…

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE),…

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do…

Fate Therapeutics (FATE) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a…